Transmitral Gradients and Mortality Following Transseptal Transcatheter Mitral Valve in Valve

Amr E Abbas1, Raj Makkar2, Amar Krishnaswamy3

  • 1Corewell Health East, William Beaumont University Hospital, Royal Oak, Michigan, USA.

Abstract

Insights

Low transvalvular mitral gradients (<4 mm Hg) after transcatheter mitral valve in valve (MVIV) procedures are linked to reduced cardiac output and increased long-term mortality. Discharge gradients should not solely determine outcomes without considering cardiac output.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Transcatheter mitral valve in valve (MVIV) procedures are increasingly common.
  • Echocardiographic transvalvular mitral gradients (TMGs) are used to assess outcomes after MVIV.
  • Limited data exists on the association between TMGs and clinical outcomes post-MVIV.

Purpose of the Study:

  • To investigate the relationship between discharge and 30-day TMGs and mortality following MVIV.
  • To evaluate the association between TMGs and other clinical outcomes post-MVIV.

Main Methods:

  • Utilized data from the Society of Thoracic Surgeons/American College of Cardiology TVT Registry (August 2015-March 2024).
  • Employed Cox proportional hazards regression models with cubic spline functions to analyze TMGs and all-cause mortality.
  • Categorized TMGs into low (<4 mm Hg), intermediate (4-7 mm Hg), and high (>7 mm Hg).
  • Generated Kaplan-Meier estimates for mortality and composite endpoints, comparing TMG ranges at discharge and 30 days.

Main Results:

  • Included 5,401 MVIV patients with a median follow-up of 377 days.
  • Low TMG (<4 mm Hg) was associated with lower cardiac output and cardiac index compared to intermediate and high TMGs.
  • Low discharge TMG correlated with increased 3-year all-cause mortality hazard (aHR: 1.52) versus intermediate TMG and (aHR: 1.35) versus high TMG.
  • Discharge and 30-day TMG measurements showed variability and should not be used interchangeably.

Conclusions:

  • TMG <4 mm Hg post-MVIV is linked to reduced cardiac output and increased 3-year mortality.
  • Significant changes in TMG occur between discharge and 30 days post-MVIV.
  • Discharge TMG alone is insufficient to determine procedural success or valve performance; cardiac output must be considered.

Related Concept Videos

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
617
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
484
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1.3K
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
502
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
855
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.6K